Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
Yıl: 2021 Cilt: 13 Sayı: 3 Sayfa Aralığı: 342 - 346 Metin Dili: İngilizce DOI: 10.4274/jcrpe.galenos.2020.2020.0051 İndeks Tarihi: 03-12-2021
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
Öz: Cases of neurofibromatosis type 1 (NF1)-associated medullary thyroid carcinoma (MTC) or C-cell hyperplasia are rarely associated with other endocrine tumors or cases with a multiple endocrine neoplasia type 2. In these patients, mutations were detected in the NF1 gene but no mutations were detected in the RET gene. Although vandetanib has been shown to improve progression-free survival in adults with advanced MTC, data in pediatric patients are limited. Herein, we report the use and outcome of vandetanib in a pediatric MTC case in which NF1 gene and RET proto-oncogen mutation were identified together.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr 2015;83:232-241. Epub 2015 Feb 5
- 2. Wong CL, Fok CK, Tam VH. Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1. Endocrinol Diabetes Metab Case Rep 2018:28;2018.
- 3. Kim BK, Choi YS, Gwoo S, Park YH, yang SI, Kim JH. Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. J Med Case Rep 2012;6:179.
- 4. Taccaliti A, Silvetti F, Palmonella G, Boscaro M. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics 2011;12:618-625.
- 5. Hansen OP, Hansen M, Hansen HH, Rose B. Multiple endocrine adenomatosis of mixed type. Acta Med Scand 1976;200:327-331.
- 6. Yoshida A, Hatanaka S, Ohi Y, Umekita Y, Yoshida H. Von Recklinghausen’s disease associated with somatostatin-rich duodenal arcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. Acta Pathol Jpn 1991;41:847-856.
- 7. Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, Jallet P, Bigorgne JC. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin. Comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:114-120.
- 8. Pages A, Marthy C, Baldet P, Péraldi R. Neurofibromatosis—thyroid medullary carcinoma—pheochromocytoma syndrome. Arch Anat Pathol 1970;18:137-142. (French)
- 9. Schimke RN. Multiple endocrine neoplasia: how many syndromes? Am J Med Genet 1990;37:375-383.
- 10. Segni Massa R, Bonifacio V, Bonifacio V, Tartaglia F, Pucarelli I, Marzullo A, Pasquino AM. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1. Horm Res 2001;56:63-66.
- 11. Gieldon L, Masjkur JR, Richter S, Därr R, Lahera M, Aust D, Zeugner S, Rump A, Hackmann K, Tzschach A, Januszewicz A, Prejbisz A, Eisenhofer G, Schrock E,Robledo M, Klink B. Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. Eur J Endocrinol 2018;178:K1-9. Epub 2017 Nov 20
- 12. Ercolino T, Lai R, Giachè V, Melchionda S, Carella M, Delitala A, Mannelli M, Fanciulli G. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. Gene 2014;536:332-335. Epub 2013 Dec 21
- 13. Edge SB, Byrd DR, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Meyer LR. AJCC Cancer Staging Manual. 7th ed. New York:Springer. 2010.
- 14. Mahalingam M. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma. Adv Anat Pathol 2017;24:1-14.
- 15. Fagin JA, Wells Jr. SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016;15:1054-1067.
- 16. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997;82:4176-4178.
- 17. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-383.
- 18. Giacché M, Panarotto A, Tacchetti MC, Tosini R, Campana F, Mori L, Cappelli C,Pirola I, Lombardi D, Pezzola DC, Casella C, Castellano M. p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy. Hum Mutat 2019;40:926-937. Epub 2019 Apr 29
- 19. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 2010;163:301-308. Epub 2010 Jun 1
- 20. Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, Aylwin S, Talat N, Beck-Peccoz P, Dralle H. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab 2010;95:E92-E97. Epub 2010 Jun 16
- 21. Tekin IM, Onay H, Aykut A, Karaca E, Atik T, Turan C, Özger G, Erdogan M, Ozkinay F. RET mutation spectrum in Turkish cases with medullary thyroid carcinoma: definition of a novel K710R mutation. J Clin Res Pediatr Endocrinol 2015;7(Suppl 2):77-92.
- 22. Türkiye Endokrin ve Metabolizma Derneği Tiroid Hastalıkları Tanı ve Tedavi Klavuzu 2019. Last Accessed date: 04.08.2021. Available from: http://temd.org.tr/admin/uploads/tbl_kilavuz/20190426165340- 2019tbl_kilavuze72e4ddf38.pdf
- 23. Laycock-van Spyk SL, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. Hum Genomics 2011;5:623- 690.
- 24. Cortés JMR, Zerón HM. Genetics of Thyroid Disorders. Folia Med (Plovdiv) 2019;61:172-179.
- 25. Herbst RS, Heymach JV, O’Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474), an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16:239-249.
- 26. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141. Epub 2011 Oct 24
- 27. Tsoli M, Alexandraki KI, Spei ME, Kaltsas GA, Daskalakis K. Antitumor activity and safety of multikinase inhibitors in advanced and/ or metastatic thyroid cancer: A systematic review and network metaanalysis of randomized controlled trials. Horm Metab Res 2020;52:25- 31. Epub 2019 Oct 30
- 28. Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019;26:241-250.
- 29. Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, Welss SA, Balis FM. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013;19:4239-4248. Epub 2013 Jun 13
- 30. Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Sherm JF, Widemann BC. Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. Clin Cancer Res 2017;24:753-765. Epub 2017 Nov 29
| APA | Gundogan B, sagcan f, tug bozdogan s, BALCI Y, tuncel daloglu f, Citak C (2021). Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. , 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| Chicago | Gundogan Begumhan,sagcan fatih,tug bozdogan sevcan,BALCI Yüksel,tuncel daloglu ferah,Citak Caglar Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. (2021): 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| MLA | Gundogan Begumhan,sagcan fatih,tug bozdogan sevcan,BALCI Yüksel,tuncel daloglu ferah,Citak Caglar Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. , 2021, ss.342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| AMA | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. . 2021; 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| Vancouver | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. . 2021; 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| IEEE | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C "Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations." , ss.342 - 346, 2021. 10.4274/jcrpe.galenos.2020.2020.0051 |
| ISNAD | Gundogan, Begumhan vd. "Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations". (2021), 342-346. https://doi.org/10.4274/jcrpe.galenos.2020.2020.0051 |
| APA | Gundogan B, sagcan f, tug bozdogan s, BALCI Y, tuncel daloglu f, Citak C (2021). Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. Journal of Clinical Research in Pediatric Endocrinology, 13(3), 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| Chicago | Gundogan Begumhan,sagcan fatih,tug bozdogan sevcan,BALCI Yüksel,tuncel daloglu ferah,Citak Caglar Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. Journal of Clinical Research in Pediatric Endocrinology 13, no.3 (2021): 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| MLA | Gundogan Begumhan,sagcan fatih,tug bozdogan sevcan,BALCI Yüksel,tuncel daloglu ferah,Citak Caglar Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. Journal of Clinical Research in Pediatric Endocrinology, vol.13, no.3, 2021, ss.342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| AMA | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. Journal of Clinical Research in Pediatric Endocrinology. 2021; 13(3): 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| Vancouver | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations. Journal of Clinical Research in Pediatric Endocrinology. 2021; 13(3): 342 - 346. 10.4274/jcrpe.galenos.2020.2020.0051 |
| IEEE | Gundogan B,sagcan f,tug bozdogan s,BALCI Y,tuncel daloglu f,Citak C "Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations." Journal of Clinical Research in Pediatric Endocrinology, 13, ss.342 - 346, 2021. 10.4274/jcrpe.galenos.2020.2020.0051 |
| ISNAD | Gundogan, Begumhan vd. "Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations". Journal of Clinical Research in Pediatric Endocrinology 13/3 (2021), 342-346. https://doi.org/10.4274/jcrpe.galenos.2020.2020.0051 |
